Miplyffa Capsule
Product Images NDC 72542-162

17 FDA label images from Acer Therapeutics Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Miplyffa (NDC 72542-162). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Acer Therapeutics Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Mip00 0004 01)

Chemical Structure (Mip00 0004 01)
Chemical structure diagram of arimoclomol citrate, the active ingredient in MIPLYFFA capsules. The structure shows molecular components including a chlorinated pyridine ring and citrate moiety.*
FDA Label Image

Figure 1 (Mip00 0004 02)

Figure 1 (Mip00 0004 02)
A line graph showing mean change from baseline in RAPIDNPCCSS over 12 months comparing MIPLYFFA with miglustat versus placebo with miglustat. The x-axis represents time since baseline (0 to 12 months), and the y-axis shows mean change values. MIPLYFFA with miglustat shows minimal change, while placebo with miglustat shows increasing mean change over time. Participant numbers at each time point are indicated below the x-axis for both groups.*
FDA Label Image

Figure A (Mip00 0004 03)

Figure A (Mip00 0004 03)
An instructional illustration showing a hand holding a small capsule or similar object, with an arrow indicating an upward twisting or pulling motion to open or separate the object. Another hand is positioned below, preparing to receive or hold it. No text or branding is visible.*
FDA Label Image

Figure B (Mip00 0004 04)

Figure B (Mip00 0004 04)
An instructional illustration showing a hand pouring capsule contents into a glass containing 15 mL of liquid. The image depicts how to empty the contents of a capsule into the liquid for oral administration.*
FDA Label Image

Figure C (Mip00 0004 05)

Figure C (Mip00 0004 05)
An instructional illustration depicting a hand holding a capsule above a glass of liquid, suggesting dropping or dissolving the capsule. A timer icon indicates a 15-second duration, likely the time to wait during the process. No text related to the product name or dosage is shown.*
FDA Label Image

Figure D (Mip00 0004 06)

Figure D (Mip00 0004 06)
An instructional black-and-white line illustration showing a person drinking from a glass with the hand holding the glass raised to the mouth. The drawing focuses on the action of oral ingestion, suitable for demonstrating how to take an oral capsule or medication by mouth.*
FDA Label Image

Figure E (Mip00 0004 07)

Figure E (Mip00 0004 07)
An instructional illustration showing a person using a syringe to draw liquid from a cup marked at 20 mL. The syringe is being held by one hand while the other hand steadies it, demonstrating liquid aspiration technique.*
FDA Label Image

Figure E (Mip00 0004 08)

Figure E (Mip00 0004 08)
Instructional illustration showing hands removing a capsule from a blister pack by pushing it upward through the foil backing, indicating how to properly extract the capsule for use.*
FDA Label Image

Figure F (Mip00 0004 09)

Figure F (Mip00 0004 09)
An instructional illustration showing hands pouring powder from a capsule into a container marked with a 20 mL measurement line. This visual depicts preparation steps likely related to the administration or measurement of the medication.*
FDA Label Image

Figure G (Mip00 0004 10)

Figure G (Mip00 0004 10)
An instructional illustration showing a hand immersing a capsule in a cup of liquid, with a timer icon indicating 15 seconds. This suggests holding the capsule in the liquid for 15 seconds before use, likely related to the administration or preparation of the MIPLYFFA capsules.*
FDA Label Image

Figure H (Mip00 0004 11)

Figure H (Mip00 0004 11)
An instructional illustration showing a hand squeezing a tube to expel its contents into a glass below, demonstrating the proper method for dissolving or preparing a medication prior to administration.*
FDA Label Image

Figure I (Mip00 0004 12)

Figure I (Mip00 0004 12)
An instructional diagram showing a syringe connected to tubing, indicating a medical injection process with a plunger labeled 'P' for pushing the liquid through the syringe. The image focuses on illustrating the correct setup or usage of the syringe and tubing assembly.*
FDA Label Image

Figure K (Mip00 0004 13)

Figure K (Mip00 0004 13)
An instructional illustration showing a syringe labeled with a 5 mL mark, accompanied by a tubing component, likely representing a medical administration setup.*
FDA Label Image

Principal Display Panel – 47 mg Carton Label (Mip00 0004 14)

Principal Display Panel – 47 mg Carton Label (Mip00 0004 14)
Packaging label for MIPLYFFA 47 mg capsules containing arimoclomol citrate for oral use. The label indicates a package size of 90 capsules. It is manufactured for Zevra Therapeutics, Inc., Boston, MA, USA, and produced in Austria. The label includes storage instructions, dosage recommendation references, and patent information. The design features the brand name, generic name, strength, and capsule images.*
FDA Label Image

Principal Display Panel – 62 mg Carton Label (Mip00 0004 15)

Principal Display Panel – 62 mg Carton Label (Mip00 0004 15)
Carton label for MIPLYFFA 62 mg capsules, an oral prescription drug containing arimoclomol citrate. The label indicates a package of 90 capsules, with manufacturer information for Zeyra Therapeutics, Inc. and storage instructions. The label includes NDC 72542-162-01 and states the product is made in Austria.*
FDA Label Image

Principal Display Panel – 93 mg Carton Label (Mip00 0004 16)

Principal Display Panel – 93 mg Carton Label (Mip00 0004 16)
Packaging label for MIPLYFFA 93 mg capsules containing arimoclomol citrate, an oral prescription drug. The label indicates 90 capsules per container, with directions for use by mouth. It includes storage instructions, patent information, and manufacturing details by Zevra Therapeutics, Inc., Boston, MA. The packaging features a primarily white and orange design with the MIPLYFFA logo.*
FDA Label Image

Principal Display Panel – 124 mg Carton Label (Mip00 0004 17)

Principal Display Panel – 124 mg Carton Label (Mip00 0004 17)
Packaging label for MIPLYFFA 124 mg capsules contains arimoclomol citrate. The label shows the product name, strength, dosage form, and container quantity of 90 capsules for oral use. It includes storage instructions, manufacturer information for Zeyra Therapeutics Inc., and states it is a prescription drug. The label also features barcodes and standard regulatory text.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.